ArticleScientific reports2026
Efferocytosis-related gene PLG in prognosis, immune correlation, and contribution to malignant behavior in vitro and in vivo of clear cell renal cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Efferocytosis plays an important role in tumor progression; however, its specific involvement in clear cell renal cell carcinoma (ccRCC) remains to be fully elucidated. In this study, efferocytosis-related genes (ERGs) were obtained from GeneCards and KEGG databases, and their expression profiles were analyzed in ccRCC using TCGA and GEO datasets. A total of 35 differentially expressed ERGs (DEGs) were identified. Among them, nine genes were found to be associated with overall survival using univariate Cox regression analysis. Consensus clustering further stratified patients into three molecular subtypes with distinct biological pathway characteristics. Subsequently, a risk score model based on six genes (PLAUR, MIAT, PLG, HAVCR1, ABCA1, and ABCG1) was constructed using LASSO regression and multivariate Cox analysis. This model stratified patients into high- and low-risk groups with significantly different survival outcomes. The risk score was significantly associated with overall survival and remained an independent factor in multivariate analysis. In addition, immune microenvironment analysis indicated that the risk score and model genes were closely related to immune characteristics. Among these genes, PLG was identified as a key gene with lower expression in tumor tissues. Functional experiments showed that PLG overexpression inhibited ccRCC cell proliferation and migration, reduced PD-L1 expression, and enhanced CD8⁺ T cell-mediated cytotoxicity. In summary, this study developed a risk score model associated with survival outcomes in ccRCC and highlighted a potential role of PLG in tumor progression and immune regulation. These findings provide a basis for further mechanistic studies and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.